Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study

Subsai Kongsaengdao,1,2 Narong Maneeton,3 Benchalak Maneeton3 1Division of Neurology, Department of Medicine, Rajavithi Hospital, Department of Medical Services, Public Health Ministry, Bangkok, Thailand; 2Department of Medicine, College of Medicine, Rangsit University, Bangkok, Thailand; 3Departme...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kongsaengdao S, Maneeton N, Maneeton B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Cervical dystonia AbobotulinumtoxinA the health-related quality of life Depressive disorder 36-Item Short Form Health Survey Cervical Dystonia Impact Profile-58 questionnaire Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/be37b59e2ac54cecb927df4822d5b834
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:be37b59e2ac54cecb927df4822d5b834
record_format	dspace
spelling	oai:doaj.org-article:be37b59e2ac54cecb927df4822d5b8342021-12-02T02:42:43ZLong-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study1178-2021https://doaj.org/article/be37b59e2ac54cecb927df4822d5b8342018-04-01T00:00:00Zhttps://www.dovepress.com/long-term-quality-of-life-in-cervical-dystonia-after-treatment-with-ab-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Subsai Kongsaengdao,1,2 Narong Maneeton,3 Benchalak Maneeton3 1Division of Neurology, Department of Medicine, Rajavithi Hospital, Department of Medical Services, Public Health Ministry, Bangkok, Thailand; 2Department of Medicine, College of Medicine, Rangsit University, Bangkok, Thailand; 3Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand Background: The short-term quality of life (QoL) in cervical dystonia (CD) after treating with abobotulinum toxin A (Abo-BTX A) and neubotulinum toxin A (Neu-BTX A) have been studied in Thai CD patients.However; the long-term study has not been published. Objective: The aim of the present study was to determine long-term improvement of the health-related quality of life (HRQoL) after eight injections of Abo-BTX A over 2 years in CD patients. Patients and methods: A 2-year prospective study on the QoL of CD patients, as measured by HRQoL, before and after receiving eight injections of Abo-BTX A at 3-month intervals over a 2-year treatment period was performed. The disease-specific HRQoL was assessed before and after the treatment by using the Cervical Dystonia Impact Profile-58 (CDIP-58) questionnaire. The general HRQoL was assessed by using the Medical Outcomes 36-Item Short Form Health Survey (SF-36), while depressive disorder screening was assessed by using the Center of Epidemiologic Studies-Depression (CES-D) questionnaire. The SF-36 and CES-D questionnaire were administered before treatment and every 3 months before the next injection for a 2-year period. Results: A total of 20 CD patients were enrolled from January 2013 to December 2015. CDIP-58 showed a significant improvement after long-term injections of Abo-BTX A in all domains (P < 0.001). However, only vitality domain of SF-36, which assessed general HRQoL, showed a significant improvement after long-term injections (P = 0.037). There was no prevalence of depressive disorder in all patients (CES-D score <20) in this study. Conclusion: The Abo-BTX A injections at 3-month intervals over a 2-year period improved the CDIP-58 scores, which assess disease-specific HRQoL, as well as an increased vitality domain of general HRQoL. No patient suffered from depression in this study. Keywords: cervical dystonia, abobotulinum toxin A, health-related quality of life, depressive disorder, 36-Item Short Form Health Survey, Cervical Dystonia Impact Profile-58 questionnaireKongsaengdao SManeeton NManeeton BDove Medical PressarticleCervical dystoniaAbobotulinumtoxinAthe health-related quality of lifeDepressive disorder36-Item Short Form Health SurveyCervical Dystonia Impact Profile-58 questionnaireNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 1119-1124 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cervical dystonia AbobotulinumtoxinA the health-related quality of life Depressive disorder 36-Item Short Form Health Survey Cervical Dystonia Impact Profile-58 questionnaire Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Cervical dystonia AbobotulinumtoxinA the health-related quality of life Depressive disorder 36-Item Short Form Health Survey Cervical Dystonia Impact Profile-58 questionnaire Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Kongsaengdao S Maneeton N Maneeton B Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study
description	Subsai Kongsaengdao,1,2 Narong Maneeton,3 Benchalak Maneeton3 1Division of Neurology, Department of Medicine, Rajavithi Hospital, Department of Medical Services, Public Health Ministry, Bangkok, Thailand; 2Department of Medicine, College of Medicine, Rangsit University, Bangkok, Thailand; 3Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand Background: The short-term quality of life (QoL) in cervical dystonia (CD) after treating with abobotulinum toxin A (Abo-BTX A) and neubotulinum toxin A (Neu-BTX A) have been studied in Thai CD patients.However; the long-term study has not been published. Objective: The aim of the present study was to determine long-term improvement of the health-related quality of life (HRQoL) after eight injections of Abo-BTX A over 2 years in CD patients. Patients and methods: A 2-year prospective study on the QoL of CD patients, as measured by HRQoL, before and after receiving eight injections of Abo-BTX A at 3-month intervals over a 2-year treatment period was performed. The disease-specific HRQoL was assessed before and after the treatment by using the Cervical Dystonia Impact Profile-58 (CDIP-58) questionnaire. The general HRQoL was assessed by using the Medical Outcomes 36-Item Short Form Health Survey (SF-36), while depressive disorder screening was assessed by using the Center of Epidemiologic Studies-Depression (CES-D) questionnaire. The SF-36 and CES-D questionnaire were administered before treatment and every 3 months before the next injection for a 2-year period. Results: A total of 20 CD patients were enrolled from January 2013 to December 2015. CDIP-58 showed a significant improvement after long-term injections of Abo-BTX A in all domains (P < 0.001). However, only vitality domain of SF-36, which assessed general HRQoL, showed a significant improvement after long-term injections (P = 0.037). There was no prevalence of depressive disorder in all patients (CES-D score <20) in this study. Conclusion: The Abo-BTX A injections at 3-month intervals over a 2-year period improved the CDIP-58 scores, which assess disease-specific HRQoL, as well as an increased vitality domain of general HRQoL. No patient suffered from depression in this study. Keywords: cervical dystonia, abobotulinum toxin A, health-related quality of life, depressive disorder, 36-Item Short Form Health Survey, Cervical Dystonia Impact Profile-58 questionnaire
format	article
author	Kongsaengdao S Maneeton N Maneeton B
author_facet	Kongsaengdao S Maneeton N Maneeton B
author_sort	Kongsaengdao S
title	Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study
title_short	Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study
title_full	Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study
title_fullStr	Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study
title_full_unstemmed	Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study
title_sort	long-term quality of life in cervical dystonia after treatment with abobotulinum toxin a: a 2-year prospective study
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/be37b59e2ac54cecb927df4822d5b834
work_keys_str_mv	AT kongsaengdaos longtermqualityoflifeincervicaldystoniaaftertreatmentwithabobotulinumtoxinaa2yearprospectivestudy AT maneetonn longtermqualityoflifeincervicaldystoniaaftertreatmentwithabobotulinumtoxinaa2yearprospectivestudy AT maneetonb longtermqualityoflifeincervicaldystoniaaftertreatmentwithabobotulinumtoxinaa2yearprospectivestudy
_version_	1718402247810875392

Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study

Ejemplares similares